Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML)

BMC Cancer

Volumn 8, Issue , 2008, Pages

  Tang, Ruoping ^a,b,c   Faussat, Anne Marie ^a,b   Perrot, Jean Yves ^c   Marjanovic, Zora ^c   Cohen, Simy ^a,b   Storme, Thomas ^c   Morjani, Hamid ^d   Legrand, Ollivier ^a,b,c   Marie, Jean Pierre ^a,b,c  

^a INSERM   (France)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c HÔTEL DIEU   (France)

^d UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTHRACYCLINE; CYCLOSPORIN A; DAUNORUBICIN; GEMTUZUMAB OZOGAMICIN; GLYCOPROTEIN P; IDARUBICIN; MITOXANTRONE; ZOSUQUIDAR; DIBENZO[A,D]CYCLOHEPTENE DERIVATIVE; QUINOLINE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIBODY SPECIFICITY; ARTICLE; CANCER ADJUVANT THERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG SENSITIVITY; FLOW CYTOMETRY; FLUORESCENCE; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL LINE; MULTIDRUG RESISTANCE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT; BIOSYNTHESIS; CELL STRAIN HL 60; COMPARATIVE STUDY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE;

CELL LINE, TUMOR; DIBENZOCYCLOHEPTENES; DRUG RESISTANCE, MULTIPLE; GENE EXPRESSION REGULATION, NEOPLASTIC; HL-60 CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; P-GLYCOPROTEIN; QUINOLINES;

EID: 40349095136     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-8-51     Document Type: Article

References (24)

1. Stock W: Controversies in Treatment of AML: Case-based Discussion. Hematology Am Soc Hematol Educ Program 2006, 185-91. 17124059
2. Marie JP, Legrand O: MDR1/P-GP expression as a prognostic factor in acute leukemias. Adv Exp Med Biol 1999, 457:1-9. Review 10500774
3. Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen IM, Head DR, Appelbaum FR, Willman CL: Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997, 89:3323-9. 9129038
4. Aegrand O, Perrot JY, Simonin G, Baudard M, Marie JP: JC-1: a very sensitive fluorescent probe to test Pgp activity in adult acute myeloid leukemia. Blood 2001, 97:502-8. 10.1182/blood.V97.2.502 11154229
5. Tallman MS: New strategies for the treatment of acute myeloid leukaemia including antibodies and other novel agents. American Society Hematology 2005, 143-150. 10.1182/asheducation-2005.1.143
6. List AF, Kopecky KJ, Willman CL, Head DR, Persons DL, Slovak ML, Dorr R, Karanes C, Hynes HE, Doroshow JH, Shurafa M, Appelbaum FR: Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: A Southwest Oncology Group study. Blood 2001, 98:3212-20. 10.1182/blood.V98.12.3212 11719356
7. Linksvan der Holt B, Löwenberg B, Burnett AK, Knauf WU, Shepherd J, Piccaluga PP, Ossenkoppele GJ, Verhoef GE, Ferrant A, Crump M, Selleslag D, Theobald M, Fey MF, Vellenga E, Dugan M, Sonneveld P: The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood 2005, 106:2646-54. 10.1182/blood-2005-04-1395 15994288
8. Wacher VJ, Wu CY, Benet LZ: Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995, 13:129-34. Review 10.1002/mc.2940130302 7619215
9. Fischer V, Rodríguez-Gascón A, Heitz F, Tynes R, Hauck C, Cohen D, Vickers AE: The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite. Drug Metab Dispos 1998, 26:802-11. 9698296
10. Sonneveld P, Burnett A, Vossebeld P, Ben-Am M, Rosenkranz G, Pfister C, Verhoef G, Dekker A, Ossenkoppele G, Ferrant C, Yin L, Gratwohl A, Kovacsovics T, Vellenga E, Capdeville R, Löwenberg B: Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia. Hematol J 2000, 1:411-21. 10.1038/sj.thj.6200050 11920222
11. Kolitz JE, George SL, Dodge RK, Hurd DD, Powell BL, Allen SL, Velez-Garcia E, Moore JO, Shea TC, Hoke E, Caligiuri MA, Vardiman JW, Bloomfield CD, Larson RA: Cancer and Leukemia Group B. Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: Final induction results of Cancer and Leukemia Group B Study 9621. J Clin Oncol 2004, 22:4290-301. 10.1200/JCO.2004.11.106 15514371
12. Shepard RL, Cao J, Starling JJ, Dantzig AH: Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979. Int J Cancer 2003, 103:121-5. 10.1002/ijc.10792 12455064
13. Dantzig AH, Shepard RL, Law KL, Tabas L, Pratt S, Gillespie JS, Binkley SN, Kuhfeld MT, Starling JJ, Wrighton SA: Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities. J Pharmacol Exp Ther 1999, 290:854-62. 10411602
14. Related Articles LinksSandler A, Gordon M, De Alwis DP, Pouliquen I, Green L, Marder P, Chaudhary A, Fife K, Battiato L, Sweeney C, Jordan C, Burgess M, Slapak CA: A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy. Clin Cancer Res 2004, 10:3265-72. 10.1158/ 1078-0432.CCR-03-0644 15161679
15. Gerrard G, Payne E, Baker RJ, Jones DT, Potter M, Prentice HG, Ethell M, McCullough H, Burgess M, Mehta AB, Ganeshaguru K: Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine. Haematologica 2004, 89:782-90. 15257929
16. Linenberger ML, Hong T, Flowers D, Sievers EL, Gooley TA, Bennett JM, Berger MS, Leopold LH, Appelbaum FR, Bernstein ID: Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood 2001, 98(4):988-94 10.1182/blood.V98.4.988 11493443
17. Walter RB, Raden BW, Hong TC, Flowers DA, Bernstein ID, Linenberger ML: Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells. Blood 2003, 102(4):1466-73. 10.1182/blood-2003-02-0396 12689934
18. Zhou DC, Ramond S, Viguié F, Faussat AM, Zittoun R, Marie J-P: Progressive resistance to homoharringtonine in human myeloleukemia K562 cells: Relationship to sequential emergence of MRP and MDR1 gene overexpression and MDR1 gene translation. Int J Cancer 1996, 65:365-71. 10.1002/(SICI)1097-0215(19960126)65:3<365::AID-IJC15<3.0.CO;2-9 8575859
19. Yanase K, Tsukahara S, Asada S, Ishikawa E, Imai Y, Sugimoto Y: Gefitinib reverses breast cancer resistance protein-mediated drug resistance. Mol Cancer Ther 2004, 3:1119-25. 15367706
20. Sarkadi B, Ozvegy-Laczka C, Nemet K, Varadi A: ABCG2 - a transporter for all seasons. FEBS Lett 2004, 567:116-20. Review 10.1016/ j.febslet.2004.03.123 15165903
21. Shepard RL, Cao J, Starling JJ, Dantzig AH: Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979. Int J Cancer 2003, 103:121-5. 10.1002/ijc.10792 12455064
22. Benderra Z, Faussat AM, Sayada L, Perrot JY, Tang R, Chaoui D, Morjani H, Marzac C, Marie JP, Legrand O: MRP3, BCRP, and P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia. Clin Cancer Res 2005, 11:7764-72. 10.1158/1078-0432.CCR-04-1895 16278398
23. Benderra Z, Faussat AM, Sayada L, Perrot JY, Chaoui D, Marie JP, Legrand O: Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias. Clin Cancer Res 2004, 10(23):7896-902. 10.1158/ 1078-0432.CCR-04-0795 15585622
24. Morschhauser F, Zinzani PL, Burgess M, Sloots L, Bouafia F, Dumontet C: Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphoma. Leuk Lymphoma 2007, 48(4):708-15. 10.1080/10428190701190169 17454628